Targeted drug aims to shrink Hard-to-Treat bile duct cancers
NCT ID NCT07701122
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with advanced biliary tract cancer whose disease has worsened after at least one prior treatment. The drug is an antibody-drug conjugate designed to seek out and deliver chemotherapy directly to cancer cells that carry a protein called TROP2. The study measures how many patients' tumors shrink or disappear, and how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab tirumotecan, an antibody-drug conjugate that targets TROP2 on cancer cells
- What this could lead to
- If effective, this could provide a new treatment option for patients with advanced biliary tract cancer who have few alternatives after standard therapy fails.
- What could go wrong
- This is a small, early-phase trial with only 33 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in most patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER(BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.